Physician profile
Deborah Shepard
NPI 1427098276
$2,178.35
in general payments reported to CMS, 2019-2025
26 companies · $43.98 in 2025
The $43.98 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $201 · 2021: $499 · 2022: $493 · 2023: $212 · 2024: $16.07 · 2025: $43.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.56 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $130.39 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.08 | 2019-2022 | |
| Amgen INC. | $113.52 | 2019-2022 | |
| Radius Health, INC. | $113.12 | 2019-2020 | |
| Evofem Biosciences, INC. | $79.28 | 2021-2022 | |
| Astellas Pharma US INC | $71.26 | 2019-2023 | Myrbetriq, Veozah |
| Coopersurgical, INC. | $70.94 | 2019-2021 | |
| Scynexis, INC. | $45.23 | 2022 | |
| Mylan Pharmaceuticals INC. | $44.34 | 2021-2022 | |
| Avion Pharmaceuticals | $43.01 | 2020-2021 | |
| Pfizer INC. | $41.72 | 2019-2024 | |
| Duchesnay USA Incorporated | $41.23 | 2019 | |
| Merck Sharp & Dohme LLC | $41.15 | 2019-2021 | |
| Therapeuticsmd, INC. | $31.79 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $29.85 | 2022-2023 | Twirla |
| Optumhealth Care Solutions, LLC | $29.60 | 2023 | Zyno Solutions, Vivify Health Care Team Portal |
| Biogen, INC. | $28.33 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $24.06 | 2021 | |
| Boston Scientific Corporation | $19.45 | 2022 | |
| Neotract INC. | $18.57 | 2019 | |
| Organon LLC | $16.13 | 2022 | |
| Sumitomo Pharma America, INC. | $15.65 | 2025 | Myfembree |
| Exeltis, USA INC. | $15.02 | 2022 | |
| Tris Pharma INC | $11.83 | 2020 | |
| Allergan, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.